TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
1-Year Return
21.62%
This Quarter Return
+10.56%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.98B
AUM Growth
+$171M
(+9.4%)
Cap. Flow
+$118M
Cap. Flow
% of AUM
5.98%
Top 10 Holdings %
Top 10 Hldgs %
35.03%
Holding
220
New
18
Increased
34
Reduced
52
Closed
20
Top Buys
| 1 |
Vera Therapeutics
VERA
|
$28.3M |
| 2 |
Merus
MRUS
|
$26.3M |
| 3 |
Mettler-Toledo International
MTD
|
$22.9M |
| 4 |
Boeing
BA
|
$20.9M |
| 5 |
Spyre Therapeutics
SYRE
|
$17.2M |
Top Sells
| 1 |
Dynavax Technologies
DVAX
|
$37.7M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$29M |
| 3 |
SLRN
ACELYRIN
SLRN
|
$24.3M |
| 4 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$10.1M |
| 5 |
CRISPR Therapeutics
CRSP
|
$9.07M |
Sector Composition
| 1 | Healthcare | 94.16% |
| 2 | Technology | 1.37% |
| 3 | Industrials | 1.32% |
| 4 | Communication Services | 1.26% |
| 5 | Consumer Discretionary | 0.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Chevron
CVX
$310B
| $750K | 0.04% |
5,239
-458
| -8% | -$65.6K |
|
177
Puma Biotechnology
PBYI
$253M
| $686K | 0.03% |
200,000
| – | – |
|
178
FedEx
FDX
$53.7B
| $657K | 0.03% |
2,892
-309
| -10% | -$70.2K |
|
|
CNTA
179
Centessa Pharmaceuticals
CNTA
$2.11B
| $657K | 0.03% |
50,000
| – | – |
|
180
Amylyx Pharmaceuticals
AMLX
$910M
| $641K | 0.03% |
100,000
| – | – |
|
181
Clorox
CLX
$15.5B
| $619K | 0.03% |
5,154
-612
| -11% | -$73.5K |
|
182
Passage Bio
PASG
$22.8M
| $600K | 0.03% |
75,000
| – | – |
|
183
Kura Oncology
KURA
$713M
| $577K | 0.03% |
100,000
| – | – |
|
184
BioAtla
BCAB
$31.5M
| $544K | 0.03% |
1,374,076
| – | – |
|
185
Astria Therapeutics
ATXS
$424M
| $536K | 0.03% |
100,000
| – | – |
|
186
OmniAb
OABI
$246M
| $522K | 0.03% |
300,000
| – | – |
|
187
Century Therapeutics
IPSC
$43.6M
| $503K | 0.03% |
900,000
| – | – |
|
188
Fortrea Holdings
FTRE
$1.06B
| $494K | 0.03% |
100,000
| – | – |
|
189
Standard BioTools
LAB
$497M
| $489K | 0.02% |
407,755
| – | – |
|
190
Cassava Sciences
SAVA
$104M
| $434K | 0.02% |
239,820
+39,820
| +20% | +$72.1K |
|
|
OKUR
191
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $404K | 0.02% |
169,245
-230,755
| -58% | -$552K |
|
192
Kodiak Sciences
KOD
$556M
| $373K | 0.02% |
100,000
| – | – |
|
193
Metagenomi
MGX
$71.7M
| $296K | 0.02% |
200,000
+65,022
| +48% | +$96.2K |
|
194
Invivyd
IVVD
$239M
| $286K | 0.01% |
400,000
| – | – |
|
195
MacroGenics
MGNX
$126M
| $265K | 0.01% |
218,856
| – | – |
|
196
Athira Pharma
ATHA
$15.4M
| $181K | 0.01% |
600,000
| – | – |
|
197
Fennec Pharmaceuticals
FENC
$250M
| $170K | 0.01% |
+20,527
| New | +$170K |
|
198
Seres Therapeutics
MCRB
$169M
| $155K | 0.01% |
13,921
+3,726
| +37% | +$41.4K |
|
|
ACTU
199
Actuate Therapeutics, Inc. Common stock
ACTU
$171M
| $32K | ﹤0.01% |
+5,243
| New | +$32K |
|
200
Galectin Therapeutics
GALT
$295M
| $27.2K | ﹤0.01% |
+12,913
| New | +$27.2K |
|